Latest Articles

Publication Date
Detecting the body's reproductive hormonal brake against tissue overgrowth: Micrin/SgII-70.

A new humoral factor has been detected, within a project aiming to disclose the body's reproductive hormonal brake against tissue overgrowth, micrin ('my-crin'). Factor purification involved fractionation of ovine and …

Published: March 2, 2026, midnight
Mechanism study of phthalate exposure promoting endometriosis: Based on the ferroptosis perspective.

Phthalates (PAEs), typical endocrine-disrupting chemicals (EDCs) that accumulate in the human body to induce reproductive toxicity, have epidemiological links to endometriosis (EM), but the underlying micro-mechanisms remain unclear. Ferroptosis is …

Published: March 2, 2026, midnight
Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis.

Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity.

Published: March 1, 2026, midnight
DRIVE-KG: Enhancing variant-phenotype association discovery in understudied complex diseases using heterogeneous knowledge graphs.

Multi-omics data are instrumental in obtaining a comprehensive picture of complex biological systems. This is particularly useful for women's health conditions such as endometriosis, which has been historically understudied despite …

Published: Feb. 28, 2026, midnight
Integrating ultrasound findings and extreme CA-125 elevation in the diagnosis of spontaneous endometrioma rupture: a case report.

Introduction: Spontaneous rupture of an endometrioma may result in life-threatening condition. Detection and prompt treatment are necessary. Presentation of Case: A 27-year-old woman presented to labor and delivery unit with …

Published: Feb. 28, 2026, midnight
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks

Published: Feb. 27, 2026, 3:24 p.m.
Sanju Pal's endometriosis case: How painful periods impact workplace performances, IVF specialist weighs... - Moneycontrol.com

Sanju Pal's endometriosis case: How painful periods impact workplace performances, IVF specialist weighs... Moneycontrol.com

Published: Feb. 27, 2026, 1:35 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!